Verastem’s Strategic Growth and Promising Clinical Data Drive Buy Rating

In a report released yesterday, Kelly Shi from Jefferies maintained a Buy rating on Verastem (VSTM – Research Report), with a price target of $19.00.

Kelly Shi has given his Buy rating due to a combination of factors surrounding Verastem’s strategic developments and promising clinical data. The company is poised for significant growth, particularly with the launch of LGSOC and the initiation of the G12D US Phase 1 study, which aims to optimize treatment protocols to manage adverse events effectively. Additionally, the recent data from the China Phase 1 study presented at ASCO demonstrated promising efficacy signals in both PDAC and NSCLC, suggesting initial durability of the treatment.
Furthermore, Verastem’s management has highlighted the unmet needs in LGSOC, expecting steady growth as patients begin and continue therapy over time. The company’s ongoing discussions with the EU agency regarding regulatory development and the planned pivotal Phase 3 study in 2026 for 1L PDAC further underscore its commitment to advancing its pipeline. These strategic initiatives, coupled with the potential for robust reimbursement and the optimization of treatment protocols, contribute to the positive outlook and Buy rating for Verastem.

According to TipRanks, Shi is an analyst with an average return of -4.4% and a 36.18% success rate. Shi covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Legend Biotech, and Verastem.

In another report released on June 3, BTIG also reiterated a Buy rating on the stock with a $20.00 price target.